Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients. - Wikidata - awgldk - TriplyDB

Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients.

Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients.

http://www.wikidata.org/entity/Q36020800

about

Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy Novel technologies and emerging biomarkers for personalized cancer immunotherapy CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition Integrating Immune Checkpoint Blockade with Anti-Neo/Mutated Antigens Reactivity to Increase the Clinical Outcome of Immunotherapy Co-Stimulatory Blockade of the CD28/CD80-86/CTLA-4 Balance in Transplantation: Impact on Memory T Cells?Control of CD8 T-Cell Infiltration into Tumors by Vasculature and Microenvironment Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation Synthetic Nanoparticles for Vaccines and Immunotherapy Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade Genetic basis for clinical response to CTLA-4 blockade in melanoma 3D: diversity, dynamics, differential testing - a proposed pipeline for analysis of next-generation sequencing T cell repertoire data Synergistic effects of the immune checkpoint inhibitor CTLA-4 combined with the growth inhibitor lycorine in a mouse model of renal cell carcinoma.Antibody-mediated neutralization of soluble MIC significantly enhances CTLA4 blockade therapy.Immune activation and a 9-year ongoing complete remission following CD40 antibody therapy and metastasectomy in a patient with metastatic melanoma.High-throughput sequencing of TCR repertoires in multiple sclerosis reveals intrathecal enrichment of EBV-reactive CD8+ T cells.Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer.Longitudinal analysis of peripheral blood T cell receptor diversity in patients with systemic lupus erythematosus by next-generation sequencing Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma.Detection and Tracking of NY-ESO-1-Specific CD8+ T Cells by High-Throughput T Cell Receptor β (TCRB) Gene Rearrangements Sequencing in a Peptide-Vaccinated Patient.Multiplex Identification of Antigen-Specific T Cell Receptors Using a Combination of Immune Assays and Immune Receptor Sequencing VDJtools: Unifying Post-analysis of T Cell Receptor Repertoires.Immune response to cancer therapy: mounting an effective antitumor response and mechanisms of resistance Association of CD8(+) T lymphocyte repertoire spreading with the severity of DRESS syndrome.Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis.Glycogen synthase kinase-3: a potential preventive target for prostate cancer management Immunological correlates of treatment and response in stage IV malignant melanoma patients treated with Ipilimumab Diversification of the antigen-specific T cell receptor repertoire after varicella zoster vaccination.Collaborating to Move Research Forward: Proceedings of the 10th Annual Bladder Cancer Think Tank.Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after Immunotherapy.Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities.DNA demethylating agent decitabine broadens the peripheral T cell receptor repertoire.What does PD-L1 positive or negative mean?TCRβ repertoire of CD4+ and CD8+ T cells is distinct in richness, distribution, and CDR3 amino acid composition.Kupfer-type immunological synapses in vivo: Raison D'être of SMAC.Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice.Beyond immune checkpoint blockade: new approaches to targeting host-tumor interactions in prostate cancer: report from the 2014 Coffey-Holden prostate cancer academy meeting.Sequencing the functional antibody repertoire--diagnostic and therapeutic discovery.T cell receptor repertoire usage in cancer as a surrogate marker for immune responses.On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation.

P2860

Q26742012-D479AE43-E5E0-490F-931D-8FD3715DD88F Q26745516-68BC31BC-8F88-4138-88EE-3E9AE17FC50C Q26770780-954D78AA-3D32-4876-ADC9-FB5DE25D444C Q26777563-6614907C-2943-436E-8443-4C53F77B3D8E Q26783783-B58248A9-E5B8-4302-A268-301AEA11589E Q26796099-0CDECC05-C661-47C6-A75C-D05E6A99D062 Q26799117-B51B3D9F-E441-492D-9DE4-F257A4B4E116 Q28075719-5CB5A096-FB6A-45C6-A669-C7CCDF6F1A00 Q28085375-E9152FC9-15E0-4437-998B-1CD9C6657A84 Q28119095-ABF98D1D-682C-44CF-8B9D-76BC7F31FF98 Q29620594-95A51F27-F296-44C8-BE52-5636924350DE Q31167209-40C9EAB9-43F1-4609-9A84-B9D7BFA60185 Q33591468-5D76FF16-EEA0-41D4-B8D0-B4725F133143 Q33699687-0A68416B-FA5B-4672-BDBB-CDBB95832D8C Q34458339-4FE415A0-5435-4918-9F1D-B1EF0FF36712 Q35221540-9BA5E9FA-3BBC-414C-925C-4E5D7550CBF7 Q35463514-C9BB47A6-8C55-420E-91C6-70DB8ADDBA27 Q35689999-4C4CDAE5-3492-4ED9-A42C-22FF5B2C5D89 Q35748121-A2351E8C-5750-4432-9D74-F05034D2867A Q35751259-D55B9084-806F-4F9E-9ECE-B91BE914931B Q35824191-E506C8EA-1A58-40C6-9FF0-BE7B69499132 Q35852353-7BF15827-D3AA-45F2-9908-C847314838F9 Q36125878-0F2E03C6-1950-424A-BBE0-F48D01D85EE1 Q36292362-00828ED7-902E-4D6E-AD24-5215FFD4E501 Q36383913-83436DED-021D-4DC6-B0C0-AD344E483FCA Q36580561-4743F4DA-CC6B-4281-B1DF-CF10A8944685 Q36821143-D55CB406-9D0D-4484-8398-07476D544640 Q36931965-AA1BF134-91E4-4D0D-A8DB-8A9101358057 Q37053881-D58AF819-E787-44AB-8FF1-F8CD5D859D24 Q37340661-B6AB3C94-437B-4817-9FB2-8A802A2A703A Q37369239-73632E62-1448-4450-B809-6834CE2852E1 Q37437334-F4F1649F-1901-4D75-AE3F-2427DADEE2F3 Q37500381-EDBAF7B2-7705-4C9B-83EA-DA79B74AD5BF Q37682074-EB7131C9-DACF-4A20-B969-B62A2B2C510E Q38255424-F0920B0A-0739-4FEB-99AB-7C858839C8C5 Q38259896-B6268205-4BD7-405D-A19D-680F5913FED6 Q38264014-4ED9582E-93F9-48E0-AF90-82107C6F9E58 Q38299138-2BAC848E-1460-40EC-93CB-728C2B973ABF Q38376433-858C3DA0-EA4F-43AD-B30C-CC160EEA277E Q38391533-78C267C3-4DA9-4945-8E5F-48E9DC2C2B2F

P2860

Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients.

http://www.wikidata.org/entity/Q36020800

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Improved survival with T cell ...... treatment in cancer patients.

@ast

Improved survival with T cell ...... treatment in cancer patients.

@en

type

label

Improved survival with T cell ...... treatment in cancer patients.

@ast

Improved survival with T cell ...... treatment in cancer patients.

@en

prefLabel

Improved survival with T cell ...... treatment in cancer patients.

@ast

Improved survival with T cell ...... treatment in cancer patients.

@en

P1433

Q36020800-45E86001-49E8-4D35-9622-4814411B8F5A

P1476

Q36020800-30C12C70-FA6C-41CD-BD98-FA9F99FA1BCE

P2093

Q36020800-1592D720-A544-4D5F-B0BE-08C7AAC5BF45

Q36020800-2951C83F-3583-4DEA-9961-8641C5864294

Q36020800-4802FD74-F750-4881-BF64-1D6C05411206

Q36020800-584F1DAE-B486-4ABD-85B6-F6DB6A1E538C

Q36020800-66BC8E65-4770-44D4-980F-884410365E7F

Q36020800-97E1C515-41F4-494D-80A6-81B4C702250D

Q36020800-EC184BEE-28AA-4D78-87FE-47C2374DC887

P2860

Q36020800-08A2B484-46C0-4AA9-B3B6-4544E48AFE9E

Q36020800-0C4249E7-33E7-4411-A9EE-DE1112411161

Q36020800-0E641E49-73FE-4823-B4BC-B91F9666B2E8

Q36020800-197F6676-9004-4702-BFC7-B99B11CC85A4

Q36020800-1F97D1D2-3EAD-44AC-BD8D-97BF67E0230E

Q36020800-305D0AC8-450A-4B48-B59F-845777D557C7

Q36020800-3268FE0C-27BB-4F62-B4C9-245AF517232D

Q36020800-375D270D-AAD1-45AA-AAB6-AC0BA7CA1E28

Q36020800-3C00ABE6-43DD-4DE1-B229-E1AFC2E8D6AF

Q36020800-3CEA4884-38AD-42E5-A23E-4168718C670B

P304

Q36020800-936F75D2-75BD-4E69-9D4C-9D928F6AEFA7

P31

Q36020800-886151EE-A545-4776-B591-A49DDE1407D0

P356

Q36020800-B65046A3-0422-449E-9877-CEA50D80212C

P407

Q36020800-D9C67F22-939A-41E5-B4EF-DE519224E49E

P433

Q36020800-1E19AF89-48E6-439B-BCBD-D60DD7E2AF4D

P478

Q36020800-AC90AB6C-4D52-4002-B147-C99EC357AD7E

P577

Q36020800-D090A8C4-15B1-480C-9CCA-92A51A72A2C9

P698

Q36020800-7915B6B7-D65E-4256-9AFD-A67D08E74CFF

P932

Q36020800-084AFD9D-F49F-4F52-96EA-0CC6A381448B

P356

SCITRANSLMED.3008211

P1433

Science Translational Medicine

P1476

Improved survival with T cell ...... treatment in cancer patients.

@en

P2093

Antoni Ribas

http://www.w3.org/2001/XMLSchema#string

Craig Cummings

http://www.w3.org/2001/XMLSchema#string

Edward Cha

http://www.w3.org/2001/XMLSchema#string

Lawrence Fong

http://www.w3.org/2001/XMLSchema#string

Malek Faham

http://www.w3.org/2001/XMLSchema#string

Mark Klinger

http://www.w3.org/2001/XMLSchema#string

Yafei Hou

http://www.w3.org/2001/XMLSchema#string

P2860

Differential expression analysis for sequence count data

Mutational heterogeneity in cancer and the search for new cancer-associated genes

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma

Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation

A molecular basis for the control of preimmune escape variants by HIV-specific CD8+ T cells

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Androgen receptor specifically interacts with a novel p21-activated kinase, PAK6

Enhancement of antitumor immunity by CTLA-4 blockade

Modulation of cell signaling networks after CTLA4 blockade in patients with metastatic melanoma

P304

238ra70

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1126/SCITRANSLMED.3008211

http://www.w3.org/2001/XMLSchema#string

P407

P433

238

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2014-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24871131

http://www.w3.org/2001/XMLSchema#string

P932

4558099

http://www.w3.org/2001/XMLSchema#string